Table 3 Recruiting researches of NRT cell and engineering TCR T cell therapy
From: Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches
Identifier | Posted Year | Cancer | Intervention | Target | Phase | Combination | Country | Status |
|---|---|---|---|---|---|---|---|---|
NCT03190941 | 2017 | gastrointestinal and pancreatic cancer | engineering TCR-T cell | HLA-A*11:01, KRAS G12V | I/II | none | United States | recruiting |
NCT03745326 | 2018 | gastrointestinal and pancreatic cancer | engineering TCR-T cell | HLA-A*02:01,KRAS-G12D | I/II | none | United States | recruiting |
NCT03412877 | 2018 | solid tumor | engineering TCR-T cell | unknown | II | Pembrolizumab | United States | recruiting |
NCT04102436 | 2019 | solid tumor | engineering TCR-T cell | unknown | II | none | Â | recruiting |
NCT03970382 | 2019 | solid tumor | engineering TCR-T cell | unknown | I | Nivolumab | United States | Suspended |
NCT04032847 | 2019 | NSCLC | NRT cells(ATL001) | mutiple neoantigens | I/II | Pembrolizumab | United Kingdom | recruiting |
NCT03997474 | 2019 | melanoma | NRT cells(ATL001) | mutiple neoantigens | I/II | Nivolumab | United Kingdom | recruiting |
NCT04146298 | 2019 | pancreatic cancer | NRT cells | HLA-A*11:01,KRASÂ G12V | I/II | Anti-PD-1 monoclonal antibody | China | recruiting |
NCT04520711 | 2020 | malignant epithelial cancer | engineering TCR-T cell | unknown | I | CDX-1140 + Pembrolizumab | United States | recruiting |
NCT05194735 | 2022 | solid tumor | engineering TCR-T cell | unknown | I/II | none | United States | recruiting |
NCT05478837 | 2022 | diffuse midline glioma | engineering TCR-T cell | HLA-A*0201, H3.3K27M | I | none | United States | not yet recruiting |